Bgm (BGM) Income towards Parent Company (2024 - 2025)
Bgm (BGM) posted quarterly Income towards Parent Company of $182.1 million for Q1 2025, up 326.08% quarter-over-quarter from $42.7 million in Q3 2024.
Bgm (BGM) Income towards Parent Company (2024 - 2025) Analysis & Trends
Bgm (BGM) has reported Income towards Parent Company for 2 consecutive years, with $182.1 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Income towards Parent Company changed N/A year-over-year to $182.1 million; the TTM figure through Mar 2025 stood at $182.1 million (changed N/A YoY), while the FY2025 annual figure was -$20.2 million, down 147.3% from the prior year.
- Income towards Parent Company improved to $182.1 million in Q1 2025 per BGM's latest filing, from $42.7 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $182.1 million in Q1 2025 and bottomed at $42.7 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Bgm | 29.89 Mn | 20.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 182.12 Mn |
| Sep 30, 2024 | 42.74 Mn |